Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

scientific article published on 01 June 2020

Advances in the development of cancer immunotherapies ⬇️

artículo científico publicado el 30 de septiembre de 2012

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

B cells and tertiary lymphoid structures promote immunotherapy response

artículo científico publicado en 2020

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

scientific article published on 11 January 2019

Comprehensive T cell repertoire characterization of non-small cell lung cancer

artículo científico publicado en 2020

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Dissecting the mechanisms of immune checkpoint therapy

artículo científico publicado en 2020

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

artículo científico publicado en 2017

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

artículo científico publicado en 2018

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

artículo científico publicado en 2017

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

artículo científico publicado en 2017

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

artículo científico publicado en 2017

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

artículo científico publicado en 2019

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

artículo científico publicado en 2019

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

artículo científico publicado en 2017

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

artículo científico publicado en 2016

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

artículo científico publicado en 2017

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells

artículo científico publicado en 2009

Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States

artículo científico publicado en 2019

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

artículo científico publicado en 2020

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

artículo científico publicado en 2021

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

scientific article published on 01 April 2020

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

artículo científico publicado en 2015

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

scientific article published on 03 March 2020

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

artículo científico publicado en 2018

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

artículo científico publicado en 2016

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

artículo científico publicado en 2020

The Human Cell Atlas

artículo científico publicado en 2017

The Human Cell Atlas

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

artículo científico publicado en 2018

The emerging role of immune checkpoint based approaches in AML and MDS.

artículo científico publicado en 2017

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Advances in the development of cancer immunotherapies ⬇️

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

B cells and tertiary lymphoid structures promote immunotherapy response

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Defining the critical hurdles in cancer immunotherapy

Dissecting the mechanisms of immune checkpoint therapy

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells

Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

The Human Cell Atlas

The Human Cell Atlas

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

The emerging role of immune checkpoint based approaches in AML and MDS.